SCHEMBL4080093

SCHEMBL4080093

CC(C)(C)OC(=O)N1CCOC(C(Cc2ccccc2OS(=O)(=O)C(F)(F)F)c2ccccc2)C1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 4/20 0.36
STS P08842 1/20 0.35
USP30 Q70CQ3 1/20 0.35
DRD2 P14416 1/20 0.35
DRD1 P21728 1/20 0.35
DRD4 P21917 1/20 0.35
DRD5 P21918 1/20 0.35
DRD3 P35462 1/20 0.35
RORC P51449 2/20 0.35
MAPT P10636 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HTR6 P50406 3/20 0.34
BCHE P06276 2/20 0.34
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
TACR1 P25103 1/20 0.34
KDM4E B2RXH2 1/20 0.33
PKM P14618 1/20 0.33
P2RX7 Q99572 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4070662 0.88 KDM1A (0.40) GPR119STSUSP30MAPTSMN1; SMN2
SCHEMBL4069724 0.84 USP30 (0.36) GPR119USP30MAPTSMN1; SMN2JAK2
SCHEMBL13483155 0.75 SLC6A2 (0.41) GPR119USP30JAK2JAK1KDM4E
SCHEMBL13482013 0.75 SLC6A2 (0.41) GPR119USP30JAK2JAK1KDM4E
SCHEMBL3194282 0.75 SLC6A2 (0.41) GPR119USP30JAK2JAK1KDM4E
SCHEMBL13482009 0.75 SLC6A2 (0.41) GPR119USP30JAK2JAK1KDM4E
SCHEMBL3197096 0.75 SLC6A2 (0.41) GPR119USP30JAK2JAK1KDM4E
SCHEMBL13483157 0.75 SLC6A2 (0.41) GPR119USP30JAK2JAK1KDM4E
SCHEMBL5940398 0.74 MMP13 (0.41) GPR119USP30MAPTSMN1; SMN2PKM
SCHEMBL3329274 0.74 USP30 (0.45) GPR119USP30RORCSMN1; SMN2JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595315-B2 Morpholine derivatives as norepinephrine reuptake inhibitors ELI LILLY AND COMPANY (US) 2009-09-29 US disclosed
EP-1716126-B1 MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS LILLY CO ELI (US) 2009-02-25 EP disclosed
US-20070060585-A1 Morpholine derivatives as norepinephrine reuptake inhibitors ELI LILLY AND COMPANY 2007-03-15 US disclosed
EP-1716126-A1 MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS ELI LILLY AND COMPANY (US) 2006-11-02 EP disclosed
WO-2005066144-A1 MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS ELI LILLY AND COMPANY (US) 2005-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060585-A1 Morpholine derivatives as norepinephrine reuptake inhibitors SLC6A2, SLC18A2, SLC6A3 GPR119 514/4885STS 1781/4885USP30 4650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.